Project Details
Description
Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are chronic and debilitating conditions affecting millions of people worldwide. Current treatment options for IBD, such as immunosuppressive drugs and anti-inflammatory agents, often provide limited relief and are associated with significant side effects. Faecal microbiota transplantation, which involves the transfer of faecal material from a healthy donor to a recipient to restore the balance of microbial communities in the recipient's gut, has emerged as a promising alternative. Recent studies suggesting that it can restore microbial diversity and improve symptoms and reduce inflammation in patients with IBD.
The IBD microbiome program will obtain novel information on the gut microbiome of Australian IBD patients compared to controls, determine whether the gut microbiome is responsible for triggering disease activity and whether modification of the gut microbiome can treat IBD. The clinical trial component rapidly tests whether FMT capsules can improve the intestinal inflammation in Crohn’s disease through a double blinded placebo-controlled randomised controlled trial. Efficacy of FMT capsules might result in acceptability of microbial manipulation as a means of treating Crohn’s disease.
The IBD microbiome program will obtain novel information on the gut microbiome of Australian IBD patients compared to controls, determine whether the gut microbiome is responsible for triggering disease activity and whether modification of the gut microbiome can treat IBD. The clinical trial component rapidly tests whether FMT capsules can improve the intestinal inflammation in Crohn’s disease through a double blinded placebo-controlled randomised controlled trial. Efficacy of FMT capsules might result in acceptability of microbial manipulation as a means of treating Crohn’s disease.
Status | Finished |
---|---|
Effective start/end date | 1/07/23 → 30/06/24 |